- Home
- AKTX
as 12-18-2024 1:30pm EST
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 29.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 91.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.90 - $4.40 | Next Earning Date: | 02-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Akari Therapeutics plc ADS News
AKTX Breaking Stock News: Dive into AKTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 hours ago
Akari Therapeutics Announces Key Leadership Appointments
GlobeNewswire
2 days ago
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer
GlobeNewswire
a month ago
Akari Therapeutics Regains Full Nasdaq Compliance
Simply Wall St.
a month ago
This Akari Therapeutics Insider Increased Their Holding By 69% Last Year
GlobeNewswire
a month ago
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
GlobeNewswire
a month ago
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
GlobeNewswire
2 months ago
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
GlobeNewswire
3 months ago
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
Compare AKTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKTX Akari Therapeutics plc ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.